ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
chrxiv-Chernyshev.pdf (1.2 MB)

Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs

preprint
submitted on 12.05.2020 and posted on 14.05.2020 by Anatoly Chernyshev
An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus. A docking study is conducted using a set of known drugs approved worldwide (ca. 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures. The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical trials.

History

Email Address of Submitting Author

a@xph.co.nz

Institution

XR Pharmaceuticals Ltd.

Country

New Zealand

ORCID For Submitting Author

0000-0002-1628-9318

Declaration of Conflict of Interest

I have no conflict of interests.

Licence

Exports

Logo branding

Licence

Exports